Decide at what price you'd be comfortable buying and we'll help you stay ready.
Novartis combines moderate revenue growth with substantial operating margins and consistently positive free cash flow. Its cash-generative model supports research, shareholder distributions, and business investment, while taxes, financing costs, and non-recurring items can make reported net income more volatile than operating performance.
The latest comparable results preserved positive operating cash generation and broadly stable quarterly operating income, but higher financing and tax costs reduced net income and increased capital spending compressed free cash flow. This represents a development in earnings and cash conversion rather than a demonstrated change in the underlying financial model.
Whether free cash flow recovers as operating cash flow improves and capital spending remains consistent with the disclosed expansion program.
| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 49.4B | 43.4B | 46B | 48.6B | 49.9B | 44B | 43.4B | 46.7B | 51.7B | 56.3B | |
| (17.3B) | (13.4B) | (13.6B) | (13.9B) | (14.4B) | (11.4B) | (11.2B) | (12B) | (12.8B) | (13.6B) | |
| 32B | 29.9B | 32.5B | 34.7B | 35.5B | 32.6B | 32.2B | 34.6B | 38.9B | 42.7B | |
| (22.9B) | (20.8B) | (22.6B) | (23.4B) | (23.2B) | (21.6B) | (22B) | (22B) | (22.6B) | (24B) | |
| (14.1B) | (12.5B) | (13.7B) | (14.3B) | (14.1B) | (12.8B) | (12.2B) | (12.5B) | (12.6B) | (13.2B) | |
| (8.4B) | (7.8B) | (8.2B) | (8.4B) | (8.5B) | (8.2B) | (9.4B) | (8.6B) | (9.3B) | (10.3B) | |
| (43m) | (187m) | (179m) | (50m) | (64m) | (109m) | — | (411m) | (209m) | (392m) | |
| (306m) | (384m) | (549m) | (607m) | (538m) | (605m) | (387m) | (498m) | (512m) | (93m) | |
| 9.2B | 9.1B | 9.9B | 11.3B | 12.3B | 11B | 10.2B | 12.6B | 16.3B | 18.7B | |
| (440m) | 418m | (11m) | 2m | 190m | 14.7B | (777m) | (497m) | (633m) | (1.1B) | |
| 709m | 741m | 877m | 780m | 775m | 692m | 699m | 792m | 938m | 1.1B | |
| (911m) | (395m) | 4.3B | (2.3B) | (2.5B) | (1B) | (2.1B) | (3B) | (2B) | (1.1B) | |
| (18m) | (19m) | (93m) | (110m) | (128m) | (108m) | (115m) | (60m) | (85m) | (176m) | |
| 7.8B | 9.1B | 14.1B | 8.9B | 9.9B | 24.5B | 7.2B | 9.1B | 13.6B | 16.4B | |
| (1.1B) | (1.6B) | (1.3B) | (1.8B) | (1.8B) | (1.6B) | (1.1B) | (551m) | (1.7B) | (2.4B) | |
| 6.7B | 7.5B | 12.8B | 7.1B | 8.1B | 22.9B | 6B | 8.6B | 11.9B | 14B | |
| 14m | 0 | (3m) | (5m) | 1m | 3m | 0 | (4m) | 2m | 17m | |
| 6.7B | 7.7B | 12.6B | 11.7B | 8.1B | 24B | 7B | 14.9B | 11.9B | 14B | |
| 2.80 | 3.24 | 5.38 | 5.05 | 3.52 | 10.62 | 3.16 | 7.09 | 5.87 | 7.15 |
Alpha Spread
Preferences
We rebuilt our DCF valuation models from the ground up and upgraded how Intrinsic Value is calculated. Alpha Spread now selects the method that best fits each company.
You can now see how the new methodology performed across thousands of stocks on our new Valuation Backtest page. We update the results at the end of every month.
New to Alpha Spread? Create free account
By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.
Already have an account? Sign in
Stock intrinsic value is the real worth of a company's stock, based on its financial health and performance.
Instead of looking at the stock's current market price, which can change due to people's opinions and emotions, intrinsic value helps us understand if a stock is truly a good deal or not.
By focusing on the company's actual financial strength, like its earnings and debts, we can make better decisions about which stocks to buy and when.
Read more